These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 1474085

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Analysis of the inhibitory effects of DuP 753 and EXP 3174 on responses to angiotensin II in the feline hindquarters vascular bed.
    Osei SY, Minkes RK, Bellan JA, Kadowitz PJ.
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1104-12. PubMed ID: 8450454
    [Abstract] [Full Text] [Related]

  • 3. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
    Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB.
    J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat.
    Lambert DG, Champion HC, Kadowitz PJ.
    Can J Physiol Pharmacol; 1998 Feb; 76(2):133-40. PubMed ID: 9635151
    [Abstract] [Full Text] [Related]

  • 5. EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells.
    Sachinidis A, Ko Y, Weisser P, Meyer zu Brickwedde MK, Düsing R, Christian R, Wieczorek AJ, Vetter H.
    J Hypertens; 1993 Feb; 11(2):155-62. PubMed ID: 8385175
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Analysis of responses to angiotensin IV in the pulmonary vascular bed of the cat.
    Cheng DY, DeWitt BJ, Dent EL, Nossaman BD, Kadowitz PJ.
    Eur J Pharmacol; 1994 Aug 11; 261(1-2):223-7. PubMed ID: 8001649
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
    Wienen W, Mauz AB, Van Meel JC, Entzeroth M.
    Mol Pharmacol; 1992 Jun 11; 41(6):1081-8. PubMed ID: 1614410
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Analysis of the effects of candesartan in the mesenteric vascular bed of the cat.
    Champion HC, Kadowitz PJ.
    Hypertension; 1997 Nov 11; 30(5):1260-6. PubMed ID: 9369285
    [Abstract] [Full Text] [Related]

  • 14. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174.
    Christ DD.
    J Clin Pharmacol; 1995 May 11; 35(5):515-20. PubMed ID: 7657853
    [Abstract] [Full Text] [Related]

  • 15. Responses to L-163,491, a nonpeptide angiotensin II mimic, in the pulmonary vascular bed of the cat.
    Kaye AD, Nossaman BD, Kivlighn S, Ibrahim IN, De Witt BJ, Kadowitz PJ.
    Eur J Pharmacol; 1995 Dec 12; 287(2):163-8. PubMed ID: 8749030
    [Abstract] [Full Text] [Related]

  • 16. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
    Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner HR.
    Clin Pharmacol Ther; 1992 May 12; 51(5):513-21. PubMed ID: 1587065
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II receptor antagonists. From discovery to antihypertensive drugs.
    Timmermans PB, Carini DJ, Chiu AT, Duncia JV, Price WA, Wells GJ, Wong PC, Wexler RR, Johnson AL.
    Hypertension; 1991 Nov 12; 18(5 Suppl):III136-42. PubMed ID: 1937677
    [Abstract] [Full Text] [Related]

  • 18. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
    Ohlstein EH, Gellai M, Brooks DP, Vickery L, Jugus J, Sulpizio A, Ruffolo RR, Weinstock J, Edwards RM.
    J Pharmacol Exp Ther; 1992 Aug 12; 262(2):595-601. PubMed ID: 1501114
    [Abstract] [Full Text] [Related]

  • 19. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
    Siegl PK, Chang RS, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, Patchett AA, Sweet CS, Lotti VJ.
    J Pharmacol Exp Ther; 1992 Jul 12; 262(1):139-44. PubMed ID: 1625193
    [Abstract] [Full Text] [Related]

  • 20. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers.
    Baan J, Chang PC, Vermeij P, Pfaffendorf M, van Zwieten PA.
    Cardiovasc Res; 1996 Nov 12; 32(5):973-9. PubMed ID: 8944829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.